The control + SFFE- and T2DM + SFFE-treated rats exhibited lower levels of glucose and HBA1c, lower hepatic levels of G6P and FBP-1, and higher hepatic levels of glucokinase, as compared to their control counterparts (control or T2DM) (Table 1). The gene discussed is FBP1; the disease is type 2 diabetes mellitus.